FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula
and ,
where the ring X represents benzole or pyridine; R1 represents substituted alkyl; R2 represents optionally substituted aryl or optionally substituted 4-7-member monocyclic heterocyclic group or optionally substituted condensed group of heterocyclic group with the benzole ring where the substitutes of optionally substituted aryl, optionally substituted 4-7-member monocyclic heterocyclic group and optionally substituted condensed group of heterocyclic group with the benzole ring are selected from a group consisting of; (1) alkyl optionally substituted by a group selected from halogen and alkoxycarbonyl, (2) alkoxy optionally substituted by halogen, (3) halogen, (4) 4-7-member monocyclic heterocyclic group or (5) amino, optionally mono- or disubstituted alkyl, and (6) hydroxyl, R3 represents hydrogen or alkyl: R4 represents hydrogen, halogen or alkyl; R5 represents hydrogen or alkyl; R6 and R7 are identical or different, and each represents hydrogen or halogen; or pharmaceutically acceptable salt. Also, the invention refers to a IKur blocker containing the compounds described above as an active ingredient, and also to a preventive and therapeutic agent for cardiac arrhythmia and atrial fibrillation.
EFFECT: there are produced and described new compounds applicable as a IKur blocker effective for preventing or treating cardiac arrhythmia, such as atrial fibrillation.
12 cl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
NOVEL DISUBSTITUTED 1,2,4-TRIAZINE COMPOUND | 2015 |
|
RU2693624C2 |
NOVEL DISUBSTITUTED 1,2,4-TRIAZINE COMPOUND | 2015 |
|
RU2726410C2 |
NEW ANTITHROMBOTIC AGENT | 2010 |
|
RU2570426C2 |
NEW THYROID HORMONE BETA-RECEPTOR AGONIST | 2010 |
|
RU2527948C2 |
CRF-RECEPTOR ANTAGONISTS AND TECHNIQUES RELATING TO THEM | 2004 |
|
RU2394035C2 |
CYCLIC HYDROCARBON JOINT | 2015 |
|
RU2676328C2 |
NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUNDS | 2012 |
|
RU2595136C2 |
AMINOINDANE DERIVATIVE OR SALT THEREOF | 2007 |
|
RU2429222C2 |
TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, USEFUL AS BB2 ANTAGONIST | 2008 |
|
RU2479578C2 |
AZULENE DERIVATIVE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT OF DIABETES MELLITUS | 2003 |
|
RU2295522C2 |
Authors
Dates
2012-03-10—Published
2008-09-26—Filed